Regeneron Pharmaceuticals' Other Non Operating Income rose 91481.48% to $176.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 10092.37%. This contributed to the annual value of $1.7 billion for FY2025, which is 10092.37% up from last year.
According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Other Non Operating Income is $176.0 million, which was up 91481.48% from $755.8 million recorded in Q3 2025.
Over the past 5 years, Regeneron Pharmaceuticals' Other Non Operating Income peaked at $755.8 million during Q3 2025, and registered a low of -$183.8 million during Q1 2022.
For the 5-year period, Regeneron Pharmaceuticals' Other Non Operating Income averaged around $169.1 million, with its median value being $165.4 million (2021).
In the last 5 years, Regeneron Pharmaceuticals' Other Non Operating Income tumbled by 26878.45% in 2021 and then skyrocketed by 193780.49% in 2022.
Regeneron Pharmaceuticals' Other Non Operating Income (Quarter) stood at -$122.2 million in 2021, then surged by 259.82% to $195.3 million in 2022, then decreased by 1.18% to $193.0 million in 2023, then crashed by 111.19% to -$21.6 million in 2024, then skyrocketed by 914.81% to $176.0 million in 2025.
Its Other Non Operating Income stands at $176.0 million for Q4 2025, versus $755.8 million for Q3 2025 and $442.8 million for Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value